Desloratadine directly binds to NMT1 to suppress the progression of HCC by inhibiting the enzymatic activity of NMT1 and subsequent VILIP3/NFκB/Bcl-2 signaling (Fig. 6h). The gene discussed is BCL2; the disease is hepatocellular carcinoma.